GEN News Highlights: Jun 4, 2010

Illumina Cuts Price for Individual Genome Sequencing Service by More than Half

Illumina Cuts Price for Individual Genome Sequencing Service by More than Half

Cost for a single person is down to $19,500 from $48,000.

(Page 1 of 1)

    Illumina has dropped its price for individual genome sequencing to $19,500. Last month the company said that the cost for an individual sequencing his/her genome was $48,000.

    Additionally, Illumina will offer a price of $14,500 per genome for groups of five or more participants using the same physician. Individuals with serious medical conditions for whom whole-genome sequencing could provide potential direct clinical value will be eligible for special pricing of $9,500 per genome.

    In all cases, the service requires individuals to follow Illumina's physician-mediated process, which involves preservice consultation, consent, and a seven-day cooling-off period, with final genome data returned to the physician.

    Illumina also announced its intention to create a World Genome Registry, a web-based resource for those who have been sequenced to record the date they were sequenced, at what coverage, and with which technology platform. This website will serve to keep the consumer genetics community updated on the current global numbers and status of individual whole-genome human sequences being generated. The company intends to create this resource and then turn it over to the community once it is established.

    “If we can stimulate the generation of more individual whole-genome sequences and the comparison of those sequences to the public databases being populated by academia, the content of the databases can be enriched and the entire field accelerated,” remarks Jay Flatley, president and CEO.

    Illumina launched its individual genome sequencing service in June 2009. Sequencing is performed in Illumina's CLIA-certified, CAP-accredited laboratory. The new prices set for individual sequencing services are a result of technology advances driving costs down, notes Flatley.


Related content

GEN News Highlights

Insight & Intelligence™

GEN Articles

BLOG biotech

Webinars

GEN Podcasts

Video Channel

New Products

Best of the Web

GEN Polls

Subscription center

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe

e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.

 

All fields are required

Email
  Confirm Email
  First Name
  Last Name
  Organization
  E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

GENpoll

FDA Performance

How much progress do you think FDA has made in reviewing drugs and bringing them to market faster?

Suggest a Poll